following a full submission:
rimegepant (Vydura®) is accepted for restricted use within NHSScotland.
Indication under review: for the acute treatment of migraine with or without aura in adults.
SMC restriction: for patients who have had inadequate symptom relief after trials of at least two triptans or in whom triptans are contraindicated or not tolerated; and have inadequate pain relief with non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol.
In three double-blind, randomised, phase III studies, significantly more patients who received acute treatment with rimegepant compared with placebo for a single migraine attack were free from pain and most bothersome symptom of migraine after 2 hours.
Download detailed advice808KB (PDF)
Medicine details
- Medicine name:
- rimegepant (Vydura)
- SMC ID:
- SMC2521
- Indication:
Acute treatment of migraine with or without aura in adults.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 May 2023